Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    RX-5902

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
    Rexahn Pharmaceuticals to Present at Two Upcoming Conferences

    13 Mar 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-present-two-upcoming-conferences

    PRESS RELEASE
    13 Mar 2018
    Share Share
    Rexahn Collab with Zhejiang Haichang Biotech for the Dev of RX-0201 Archexin®
    Rexahn Collab with Zhejiang Haichang Biotech for the Dev of RX-0201 Archexin®

    08 Feb 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-announces-collaboration-zhejiang-haichang

    PRESS RELEASE
    08 Feb 2018
    Share Share
    Rexahn Receives Notice of Allowance for A New U.S. Patent-RX-5902 (Supinoxin™)
    Rexahn Receives Notice of Allowance for A New U.S. Patent-RX-5902 (Supinoxin™)

    29 Jan 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-receives-notice-allowance-new-us-patent-0

    PRESS RELEASE
    29 Jan 2018
    Share Share
    Rexahn New Preclinical Data on Supinoxin™ at 2017 S.A Breast Cancer Symposium
    Rexahn New Preclinical Data on Supinoxin™ at 2017 S.A Breast Cancer Symposium

    11 Dec 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-presents-new-preclinical-data-supinoxintm

    PRESS RELEASE
    11 Dec 2017
    Share Share
    Rexahn Announces $8 Million Registered Direct Offering
    Rexahn Announces $8 Million Registered Direct Offering

    13 Oct 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-announces-8-million-registered-direct-offering

    PRESS RELEASE
    13 Oct 2017
    Share Share
    Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
    Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™

    13 Aug 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-receives-new-us-patent-supinoxintm

    PRESS RELEASE
    13 Aug 2017
    Share Share